Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
作者： P McLaughlin , F B Hagemeister , F Swan , F Cabanillas , O Pate
DOI: 10.1200/JCO.1994.12.3.575
关键词:
摘要: PURPOSEFludarabine is an active agent for patients with low-grade lymphoma (LGL) but has mainly been used as a single agent. This trial was designed to define the maximum-tolerated dose (MTD) of combination fludarabine, mitoxantrone, and dexamethasone (FND), identify toxicities these agents in combination, make preliminary observations about efficacy this combination.PATIENTS AND METHODSTwenty-one recurrent LGL or follicular large-cell were treated, cohorts three, at stepwise escalating doses. Patients required have adequate marrow function normal renal, hepatic, cardiac function.RESULTSThe MTD found be follows: 25 mg/m2/d (days 1 3); 10 mg/m2 (day 1); dexamethasone, 20 mg/d 5). Each course administered monthly, up eight courses given. Dose-limiting neutropenia infections. Thrombocytopenia modest. Nonhematologic toxicity...
sci-hub.se 参考文章(16)
Eric H. Kraut, Louis Malspeis, Kathy M. Snider, Michael R. Grever, Earl N. Metz, Jane M. Leiby, Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Research. ,vol. 47, pp. 2719- 2722 ,(1987)
H S Hochster, K M Kim, M D Green, R B Mann, R S Neiman, M M Oken, P A Cassileth, P Stott, P Ritch, M J O'Connell, Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology. ,vol. 10, pp. 28- 32 ,(1992) , 10.1200/JCO.1992.10.1.28
R T Silver, D C Case, R H Wheeler, T P Miller, R S Stein, J J Stuart, B A Peterson, S E Rivkin, H M Golomb, Costanzi, Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. Journal of Clinical Oncology. ,vol. 9, pp. 754- 761 ,(1991) , 10.1200/JCO.1991.9.5.754
J R Redman, F Cabanillas, W S Velasquez, P McLaughlin, F B Hagemeister, F Swan, M A Rodriguez, W K Plunkett, M J Keating, Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. Journal of Clinical Oncology. ,vol. 10, pp. 790- 794 ,(1992) , 10.1200/JCO.1992.10.5.790
P McLaughlin, M Fridrik, S Tucker, S Jagannath, FB Hagemeister, JR Redman, F Swan, WS Velasquez, F Cabanillas, P Salvador, Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. ,vol. 71, pp. 117- 122 ,(1988) , 10.1182/BLOOD.V71.1.117.117
H G Chun, B Leyland-Jones, B D Cheson, Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. Journal of Clinical Oncology. ,vol. 9, pp. 175- 188 ,(1991) , 10.1200/JCO.1991.9.1.175
L. Jones, F. E. Cotter, D. Lord, A. C. Newland, Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkins lymphoma Hematological Oncology. ,vol. 8, pp. 41- 45 ,(1990) , 10.1002/HON.2900080106
G.C. Kane, A.J. McMichael, H. Patrick, A.J. Erslev, Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate Respiratory Medicine. ,vol. 86, pp. 261- 263 ,(1992) , 10.1016/S0954-6111(06)80066-1
RichardA. Gams, Shelley Bryan, Gary Dukart, Arnold Weiss, Delvyn Case, Stephen Jones, Richard Stein, Mitoxantrone in malignant lymphoma Investigational New Drugs. ,vol. 3, pp. 219- 222 ,(1985) , 10.1007/BF00174174
SteenWerner Hansen, NisI. Nissen, MogensM�rk Hansen, Klaus Hou-Jensen, Jens Pedersen-Bjergaard, High activity of mitoxantrone in previously untreated low-grade lymphomas. Cancer Chemotherapy and Pharmacology. ,vol. 22, pp. 77- 79 ,(1988) , 10.1007/BF00254186